Editorial Article: Accelerated production of novel immunotherapies with high-throughput screening
Dr. Dallas Flies, Vice President, Discovery Research, NextCure, Inc. discusses the cutting-edge technology transforming the identification of new targets for the development of effective immunotherapeutics
29 Jul 2021
Dr. Dallas Flies, Vice President, Discovery Research, NextCure, Inc.
A major challenge in the development and production of immunotherapeutics is the shortage of novel targets that can be exploited. To tackle this, NextCure, a fully integrated clinical-stage biopharmaceutical company, is working hard to accelerate the development of cancer therapeutics and improve patient care, by identifying potential targets through advanced high-throughput screening techniques such as flow cytometry and cell sorting.
Dallas
Texas
United-states
Discovery-research
Discovery-research-at-nextcure
Discovery-research-department
Nextcure-inc
Editorial-article
Dallas-flies
Vice-president
Cell-sorter